We found that both BBR monotherapy and combination therapy significantly improved inflammatory markers, including reductions in CRP, IL-6, and TNF-α levels, further confirming the potential value of BBR in the comprehensive management of T2DM. The gene discussed is IL6; the disease is type 2 diabetes mellitus.